title: Management of polysensitized patient: from molecular diagnostics to biomolecular immunotherapy.
abstract: A panel of Italian allergists gathered to discuss the issue concerning the management of polysensitized patients. The main conclusions were as follows: polysensitization is a relevant clinical characteristic as it affects about 70-80% of the global allergic population; the diagnostic pathway needs the use of an adequate and thorough methodology, based on the demonstration of consistency between history and documented sensitization; polysensitization and polyallergy are not synonymous: true allergy should always be demonstrated; polysensitization does not constitute a limitation to allergen immunotherapy prescription, as 1-2 allergen extracts could be effective in polysensitized patients; the allergen immunotherapy product characteristics should include the following: high efficacy and optimal safety profile, standardized production, and documented presence and titration of the major allergen.
authors.affiliation: IRCCS-AOU San Martino di Genova, Genoa, Italy.
authors.forename: Giorgio
authors.initials: G
authors.lastname: Ciprandi
authors.forename: Cristoforo
authors.initials: C
authors.lastname: Incorvaia
authors.forename: Franco
authors.initials: F
authors.lastname: Frati
mesh_terms: D000485:Allergens / Q000276:immunology*; D003888:Desensitization, Immunologic / Q000379:methods*; D003937:Diagnosis, Differential; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D018777:Multiple Chemical Sensitivity / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy*; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000485:Allergens
keywords: allergy; immunotherapy; management; molecular allergens; polysensitization